Previous close | 393.48 |
Open | 394.72 |
Bid | 394.09 x 100 |
Ask | 394.48 x 100 |
Day's range | 391.25 - 396.98 |
52-week range | 316.43 - 448.40 |
Volume | |
Avg. volume | 1,214,969 |
Market cap | 101.905B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 28.39 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.